Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
Jeffrey A SparksZachary S WallaceAndrea M SeetMilena A GianfrancescoZara IzadiKimmie L HyrichAnja StrangfeldLaure GossecLoreto CarmonaElsa F MateusSaskia Lawson-ToveyLaura TrupinStephanie RushPatricia KatzGabriela SchmajukLindsay JacobsohnLeanna WiseEmily L GilbertAli Duarte GarciaMaria O Valenzuela-AlmadaGuillermo J Pons-EstelCarolina A IsnardiGuillermo A BerbottoTiffany Y-T HsuKristin M D'SilvaNaomi J PatelLianne Kearsley-FleetMartin SchäferSandra Lucia Euzébio RibeiroSamar Al EmadiLiselotte TidbladAnd Carlo Alberto ScirèBernd RaffeinerThierry ThomasRené-Marc FlipoJérôme AvouacRaphaèle SerorMiguel BernardesMaria Margarida CunhaRebecca HasseliHendrik Schulze-KoopsUlf Müller-LadnerChristof SpeckerViviane Angelina de SouzaLicia Maria Henrique da MotaAna Paula Monteiro Gomides ReisPhilippe DieudeElena NikiphorouVanessa L KronzerNamrata SinghManuel Francisco Ugarte-GilBeth WallaceAkpabio AkpabioRanjeny ThomasSuleman BhanaWendy CostelloRebecca GraingerJonathan S HausmannJean W LiewEmily SirotichPaul SufkaPhilip C RobinsonPedro M MachadoJinoos Yazdanynull nullPublished in: Annals of the rheumatic diseases (2021)
People with RA treated with RTX or JAKi had worse COVID-19 severity than those on TNFi. The strong association of RTX and JAKi use with poor COVID-19 outcomes highlights prioritisation of risk mitigation strategies for these people.